Identification of novel IGRP epitopes targeted in type 1 diabetes patients

Irene Jarchum, Lynn Nichol, Massimo Trucco, Pere Santamaria, Teresa P. DiLorenzo

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


CD8+ T cells play an important role in the development of type 1 diabetes (T1D) in NOD mice and humans. IGRP (islet-specific glucose-6-phosphatase catalytic subunit-related protein) has emerged in recent years as a major antigen in NOD mice. Therefore, we aimed to determine if IGRP is an antigen in T1D patients and to identify the HLA-A2-restricted IGRP epitopes targeted. Using IFN-γ ELISPOT assay, we tested PBMC from recent-onset pediatric T1D patients and healthy controls for reactivity to four IGRP peptides directly ex vivo. Importantly, 65% of patients and 0% of controls were positive for at least one IGRP peptide. Two of these have not been reported previously. These data provide evidence that IGRP is a CD8+ T cell antigen in humans, contributing to the understanding of the underlying disease process as well as to future directions for diagnosis and monitoring disease progression in T1D patients.

Original languageEnglish (US)
Pages (from-to)359-365
Number of pages7
JournalClinical Immunology
Issue number3
StatePublished - Jun 2008


  • Antigens
  • Autoimmunity
  • Diabetes
  • Human
  • IGRP
  • T cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Identification of novel IGRP epitopes targeted in type 1 diabetes patients'. Together they form a unique fingerprint.

Cite this